Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical...

Area of Science:

• Oncology
• Immunotherapy
• Virology

Background:

• Cancer immunotherapy has advanced significantly, with immune checkpoint inhibitors (ICI) becoming crucial in treating various cancers.
• Oncolytic viruses are emerging as a promising therapeutic strategy, showing encouraging results in clinical trials.
• Combining oncolytic viruses with conventional treatments like chemotherapy and radiotherapy is under extensive investigation.

Purpose of the Study:

• To review clinical trial data on oncolytic viruses, focusing on their efficacy and safety.
• To identify and highlight the most promising combinations of oncolytic viruses with other immunotherapies and treatments.
• To provide insights into future strategies for cancer treatment using virus immunotherapy.

Main Methods:

• Systematic review of published clinical trial data on oncolytic virus therapy.
• Analysis of combinations involving oncolytic viruses with immune checkpoint blockade, cytokines, antigens, and other oncolytic viruses.
• Evaluation of efficacy and safety data from clinical studies.

Main Results:

• Oncolytic viruses, with or without genetic modifications, show potential when combined with immune checkpoint blockade and other agents.
• Several combinations are demonstrating encouraging outcomes in clinical settings.
• The review focuses on published clinical data to identify effective therapeutic strategies.

Conclusions:

• Virotherapy, particularly in combination with other immunotherapies, represents a significant advancement in cancer treatment.
• Further research into optimizing oncolytic virus combinations is essential for maximizing therapeutic benefits.
• Future perspectives suggest novel strategies for cancer treatment through advanced virus immunotherapy.